Recent reports in an experimental tumour cell system (Brodie et al, 2001) and also based on clinical observations (Kloos et al, 2001) appear to show conflicting results indicating that BRCA1 inactivation might indeed result in increased doxorubicin sensitivity. Here, BRCA1 is linked to neoplasm.